The short answer
A CoQ10-related increase in low blood pressure with indapamide has not been established. Review use with your prescriber, particularly if you already have dizziness or low readings.
What this answer covers
Oral coenzyme Q10 (ubidecarenone) with indapamide. Evidence from combination supplements, other quinones or unspecified antihypertensive regimens is not exact-pair evidence.
- Supplement or preparation
- Coenzyme Q10
- Medication ingredient
- indapamide
The relevant trial was not clearly positive
Thirty people with metabolic syndrome took CoQ10 or placebo while their usual blood-pressure medicines stayed unchanged. CoQ10 did not significantly reduce average 24-hour systolic or diastolic pressure. Some secondary measurements improved, but the trial did not establish a harmful indapamide interaction.
Why the exact combination remains uncertain
People, products and background medicines differ. The inspected abstract does not identify an indapamide subgroup, and one small trial cannot rule out individual reactions. A proposed blood-pressure effect is not enough to predict that the combination will cause hypotension.
Discuss your reason for taking CoQ10
Show the prescriber the product, dose and other ingredients, and explain what you want it to help. If you start or change it, ask whether your blood-pressure plan needs review. The evidence supplies no fixed indapamide dose change or protective spacing interval.
Do not overlook other causes of dizziness
Indapamide can cause fluid or electrolyte disturbances as well as low pressure. Tell your care team about persistent dizziness, weakness or near-fainting and any recent illness or medication change. CoQ10 should not replace prescribed blood-pressure treatment.
Evidence and practical considerations
Side effects & toxicity
Evidence does not establish that CoQ10 increases the risk of low blood pressure specifically with indapamide.
- Exact scope
- Oral coenzyme Q10 (ubidecarenone) with indapamide. Evidence from combination supplements, other quinones or unspecified antihypertensive regimens is not exact-pair evidence. with Exact indapamide RxCUI 5764 IN, confirmed by current NLM properties. Oral indapamide dose and release formulation are retained; evidence for hydrochlorothiazide, other diuretics or combination antihypertensive products is not automatically equivalent.
- Medication form and route
- Oral
What remains uncertain
- A small add-on study found no significant average 24-hour pressure reduction; background treatment was not resolved as an exact indapamide subgroup. This does not prove universal safety.
Factors that may matter: Dose and duration; Exact supplement preparation; Kidney function; Other medicines; Baseline electrolyte status.
Read the supporting source summaries
Source 1: Current U.S. prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed oral indapamide 1.25 or 2.5 mg tablets; additional dose-ranging study data.
Recommends periodic electrolyte and renal-function assessment. Potassium reductions were dose-related; some low measurements normalized without intervention. Calcium increases in indapamide studies were only slight. Includes a thiazide-like magnesium-loss warning.
How this applies: Exact medication guidance with explicit dose and nutrient distinctions. Exact indapamide RxCUI 5764 IN, confirmed by current NLM properties. Oral indapamide dose and release formulation are retained; evidence for hydrochlorothiazide, other diuretics or combination antihypertensive products is not automatically equivalent.
A label class warning is not proof that every patient has magnesium depletion or that routine supplements are required. Higher-dose risks and other diuretics cannot be assigned to every low-dose regimen.
Source 2: Original clinical research
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 30 adults with metabolic syndrome and inadequately controlled hypertension on unchanged medicines.
No significant reduction in mean 24-hour systolic or diastolic blood pressure; no clinically relevant safety changes. Some secondary diastolic-load measures improved.
How this applies: Counterevidence to assuming CoQ10 consistently adds a clinically important antihypertensive effect; no direct indapamide conclusion.
Small trial, background drugs not resolved as an exact indapamide subgroup in the inspected abstract. A null average effect does not prove safety for every person.
Source 3: Authoritative medication terminology
rxnav.nlm.nih.gov · Source check Sep 10, 2026
Population: Medication terminology.
Identifies indapamide as IN.
How this applies: Exact medication identifier.
Does not establish formulation equivalence or a clinical interaction.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Sources checked and article drafted. | |
| Research summary published |
Article revision: 57715e0aad977409
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.